Growing Up with Duchenne Muscular Dystrophy: Advances in Treatment and Quality of Life

Duchenne muscular dystrophy (DMD) is a rare, progressive, and complex neuromuscular disease affecting primarily males. It stems from a genetic defect that impairs the production of dystrophin, a protein crucial for maintaining muscle function. A recent documentary, Growing Up with Duchenne, promoted by the Fondazione Policlinico Universitario Agostino Gemelli IRCCS, highlights the clinical aspects of the disease, as well as the personal and social experiences of those living with it and their families.

The Stories of Luca, Hermes, and Enrico

The documentary centers on three young men – Luca (19), Hermes (14), and Enrico (20) – and their families, offering a deeply personal look into life with DMD. Luca emphasizes the importance of not being defined solely by his condition, stating his commitment to setting goals and facing challenges with determination. Hermes expresses a desire to be seen as an individual, not just a patient, and hopes for increased attention to the needs of adolescents with DMD. Enrico, through his involvement in powerchair football, demonstrates how sports can provide a sense of freedom, expression, and autonomy despite physical limitations. He emphasizes appreciating abilities and persevering despite challenges.

The Parents’ Perspective

The documentary likewise features the perspectives of parents navigating the complexities of raising children with DMD. Their testimonies reveal the daily realities of care, adaptation, and future concerns, alongside hope and belief in their children’s potential. Parents discuss the delicate balance between providing support and fostering independence, the emotional toll of witnessing their children’s physical changes, and the strength required to support their aspirations.

Advances in Survival and Treatment

Historically, survival with DMD was limited to around 18 years. However, Professor Eugenio Mercuri, director of the Department of Women’s and Children’s Health at the Gemelli Polyclinic and professor of Child Neuropsychiatry at the Catholic University of the Sacred Heart, explains that advancements in care have significantly improved outcomes. Average survival rates now reach around 30 years, with an increasing number of individuals exceeding this milestone. The introduction of corticosteroids, and more recently, therapies targeting the gene level or directly impacting muscle function, have slowed disease progression and delayed the loss of mobility. Where loss of walking ability previously occurred around 7-8 years of age, it now occurs, on average, around 14 years of age.

Challenges in Adolescence and Emerging Therapies

Despite these improvements, DMD remains a serious condition requiring multidisciplinary and continuous care, particularly during the transition from childhood to adulthood. Professor Mercuri notes that adolescence is a sensitive period, requiring attention to both clinical stabilization and quality of life. While steroid treatments are essential, they can have side effects affecting bone health, growth, and pubertal development. Emotional challenges also arise as patients compare themselves to peers. Research is focused on developing new steroid medications with fewer side effects, as well as innovative drugs aimed at increasing dystrophin production and reducing muscle inflammation. While the United States has a greater number of approved drugs, Europe currently has one approved anti-inflammatory muscle treatment, with many others undergoing testing. These treatments aim to stabilize the disease, extend life expectancy, and improve quality of life.